G-protein-coupled receptors (GPCRs) signal primarily through G proteins or arrestins. Arrestin binding to GPCRs blocks G protein interaction and redirects signalling to numerous G-protein-independent pathways. Here we report the crystal structure of a constitutively active form of human rhodopsin bound to a pre-activated form of the mouse visual arrestin, determined by serial femtosecond X-ray laser crystallography. Together with extensive biochemical and mutagenesis data, the structure reveals an overall architecture of the rhodopsin-arrestin assembly in which rhodopsin uses distinct structural elements, including transmembrane helix 7 and helix 8, to recruit arrestin. Correspondingly, arrestin adopts the pre-activated conformation, with a 206 rotation between the amino and carboxy domains, which opens up a cleft in arrestin to accommodate a short helix formed by the second intracellular loop of rhodopsin. This structure provides a basis for understanding GPCR-mediated arrestin-biased signalling and demonstrates the power of X-ray lasers for advancing the frontiers of structural biology.
G-protein-coupled receptors (GPCRs) comprise the largest family of cell surface receptors, which signal primarily via G proteins or arrestins 1,2 . Upon activation, GPCRs recruit heterotrimeric G proteins and subsequently G-protein-coupled receptor kinases (GRKs), which phosphorylate GPCRs to allow the high-affinity binding to arrestin 3 . Arrestin binding to the receptors blocks their interactions with G proteins and leads to the receptor's desensitization 4 . The binding of arrestins to GPCRs also initiates numerous cellular signalling pathways that are independent of G proteins. Arrestin-mediated signalling is therefore a central component of the GPCR functional network.
GPCRs are targets of one-third of the current clinically used drugs. Recent studies have demonstrated that G-protein and arrestin pathways are distinct and can be pharmacologically modulated independently using biased GPCR ligands 5 . Biased GPCR ligands are often preferred over unbiased agonists and antagonists, as they selectively direct the receptor to a subset of partners and can deliver therapeutic benefits with fewer undesirable side effects. Research towards biased ligands has become a new trend for GPCR-targeting therapeutics 6 . The molecular mechanisms of GPCR signalling have been unravelled by recent breakthroughs in GPCR structural biology [7] [8] [9] [10] . In the antagonist-bound state, GPCRs assume a closed conformation with the cytoplasmic ends of the transmembrane (TM) helices packed closely with each other 7, 9 , thus blocking the interactions with G proteins or arrestins. In contrast, agonist binding promotes conformational changes in GPCRs, including a dramatic movement within the cytoplasmic side of the TM domain 8, [11] [12] [13] [14] , thus allowing activated receptors to recruit G proteins or arrestins to mediate downstream signalling. However, arrestin coupling to GPCRs may require a conformation of the receptor different from that required for coupling with G proteins 14, 15 . Rhodopsin is a prototypical GPCR responsible for light perception 7 . Along with the b 2 -adrenergic receptor (b 2 AR), rhodopsin has served as a model system for studying GPCR signalling 16 . Figure 1a shows rhodopsin binding to G protein and arrestin. Light induces isomerization of 11-cis retinal to all-trans-retinal (ATR), which activates rhodopsin and promotes its interactions with G protein 17, 18 . Lightactivated rhodopsin is then phosphorylated by rhodopsin kinase (GRK1), leading to high affinity recruitment of arrestin that terminates the G protein signalling. Activation of rhodopsin can also be achieved through mutations, including the E113 3.28 Q/M257 6.40 Y mutation, which yields a constitutively active rhodopsin 19 (superscripts in residues refer to the Ballesteros-Weinstein numbering 20 ). The crystal structure of bovine rhodopsin has been determined in the inactive, resting state 7 , the ligand-free state 21, 22 , and the ligand-activated state in complex with a G-protein peptide 23 . Arrestin structures have been determined in the inactive 24, 25 and pre-activated form 1, 2 . Recent electron microscopy analysis has revealed the assembly and conformational dynamics of the b 2 AR-b-arrestin complex 26 . Here we report the crystal structure of an active form of human rhodopsin bound to a pre-activated mouse visual arrestin, determined by serial femtosecond crystallography (SFX). The structure has been confirmed by electron microscopy, double electron-electron resonance (DEER) spectroscopy, hydrogen-deuterium exchange mass spectrometry (HDX), cell-based rhodopsin-arrestin interaction assays, and site-specific disulfide crosslinking experiments. Our study provides a molecular basis for understanding GPCR-mediated arrestin-biased signalling.
Characterization and crystallization
To characterize the rhodopsin-arrestin interaction, we expressed and purified E113
3.28 Q and E113 3.28 Q/ M257 6.40 Y mutant receptors (Extended Data Fig. 1a ). These mutations were introduced in the context of the N2 Nterm C/N282 ECL3 C mutant that is known to create a disulfide bond that increases rhodopsin stability without affecting its activity [27] [28] [29] . The N2 Nterm C/N282 ECL3 C mutant is referred to as our wild-type control. To determine the interaction between rhodopsin and arrestin, we developed a bead binding pull-down assay. In this assay, rhodopsin expressed as a fusion with a maltose-binding protein (MBP) at its N terminus was bound to amylose beads, which were then used to pull down in vitro translated arrestin labelled with 35 S. Wild-type arrestin has weak background binding to wildtype rhodopsin (Fig. 1b) . The E113 3.28 Q mutation increased wild-type arrestin binding by twofold to threefold, and the E113 3.28 Q/ M257 6.40 Y mutation further increased the binding of wild-type arrestin in the presence of all-trans-retinal (fourfold to eightfold). In contrast to the relatively weak binding of wild-type arrestin, the binding of 3A arrestin, a pre-activated form of arrestin that obviates the need for receptor phosphorylation for high affinity binding through three alanine mutations in L374, V375, and F376 in the C-terminal tail of arrestin, is much stronger. In the absence of all-trans-retinal, we observed a nearly 30-fold increase of 3A arrestin binding to the E113 3.28 Q/M257 6.40 Y receptor. All-trans-retinal further increased 3A arrestin binding to the E113 3.28 Q/M257 6.40 Y receptor by ,60-fold above the binding of wild-type arrestin to wild-type rhodopsin (Fig. 1b and Extended Data Fig. 1b) .
We also measured rhodopsin-arrestin interactions using AlphaScreen assays (Extended Data Fig. 1c ) with His 8 -tagged rhodopsin and biotin-tagged arrestin. Wild-type arrestin interacted weakly with the E113 3.28 Q/M257 6.40 Y rhodopsin, regardless of the presence of all-trans-retinal (Fig. 1c) . As a positive control, the GaCT-HA peptide, a high affinity peptide variant of the C terminus of G-transducin (G t ) 30 , readily interacted with the E113 3.28 Q/M257 6.40 Y receptor in the absence of all-trans-retinal, and addition of all-trans-retinal slightly increased this interaction (Extended Data Fig. 1d ). Quantitative competition using unlabelled 3A arrestin or GaCT-HA with the E113 3.28 Q/M257 6.40 Y receptors revealed an IC 50 value of 15 nM and 700 nM for the binding of 3A arrestin and the GaCT-HA peptide, respectively ( Fig. 1d and Extended Data Fig. 1d ). The strength of the interaction between the E113 3.28 Q/M257 6.40 Y rhodopsin and the 3A arrestin is in a similar range as the estimated K d value of 30-80 nM for the binding of arrestin to the fully activated phosphorylated rhodopsin 31 . Mixing individually purified proteins did not yield a stable 1:1 complex, nor did it lead to crystallization. Extensive biochemical data support a 1:1 stoichiometry in the rhodopsin-arrestin complex 32, 33 . Therefore, we engineered a fusion protein in which 3A arrestin is linked by a 15-residue linker to the C terminus of E113 3.28 Q/M257
6.40 Y rhodopsin. We expressed and purified the rhodopsin-arrestin fusion protein, as well as a T4 lysozyme (T4L)-rhodopsin-arrestin fusion, in which a T4L is fused to the N terminus of rhodopsin to increase the soluble surface for crystallization (Extended E113Q M257Y
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E113Q M257Y Y) protein to biotin-MBP-arrestin (wild type (WT) and 3A) measured by AlphaScreen in the absence or presence of 5 mM ATR. The first six columns are controls (luminescence signals in the presence of only one of the binding partners; n 5 3, error bars, s.d.). d, Competition of arrestin binding to rhodopsin was determined by a homologous AlphaScreen assay and the IC 50 value was derived from repeat experiments (n 5 3, error bars, s.d.). e, Negative stain electron microscopy images of rhodopsin-arrestin complexes without or with T4L at the N terminus; right panel, overlay of the electron microscopy image with the structures of T4L, rhodopsin and arrestin. m, detergent micelle. Data Fig. 2a) . The T4L-rhodopsin-arrestin fusion protein is monomeric and relatively stable with a T m of 59 uC (Extended Data Fig. 2b Y rhodopsin and 3A arrestin form a stable complex with arrestin bound to the cytoplasmic side of rhodopsin (Fig. 1e) . The T4L-rhodopsin-arrestin fusion protein formed crystals with sizes in the range of 5 to 15 mm under various lipid cubic phase (LCP) crystallization conditions (Extended Data Fig. 2d, e) . Despite extensive optimization, the crystals diffracted only to 6-8 Å at synchrotron sources (Extended Data Fig. 2f ). We thus turned our attention to the emerging method of SFX 34 with an LCP injector (LCP-SFX) 35, 36 .
Arrestin

Structure determination by SFX
Because of the small size of crystals, we hypothesized that diffraction by X-ray free electron laser (XFEL) at the Linac Coherent Light Source (LCLS) would improve data quality given the advantages of intense and very short XFEL pulses for micrometre-size crystals. In the LCP-SFX method, a stream of gel-like LCP with fully hydrated microcrystals runs continuously in vacuum across the 1.5-mm-diameter XFEL beam, which delivers 120 X-ray pulses per second with less than 50 fs pulse duration and sufficient intensity to capture crystal diffraction patterns with a single pulse. Within ,12 h of run time, we collected over 5 million detector frames, of which 22,262 had more than 40 diffraction spots as determined by the Cheetah hit-finding software 37 .
Diffraction patterns from 18,874 crystals could be indexed and integrated using CrystFEL 38 . The data were processed according to the apparent tetragonal lattice with a large unit cell (a 5 b 5 109.2 Å and c 5 452.6 Å ). The diffraction was anisotropic with resolution limits of 3.8 Å and 3.3 Å along the a*/b* and c* axes, respectively (Supplementary Table 1 ).
The crystals appeared to be pseudo-merohedrally twinned in P2 1 2 1 2 1 (Supplementary Table 2 ) and the structure was solved by molecular replacement using known structures of active rhodopsin 39 and pre-activated arrestin 1 (details in Methods). The structure contains four rhodopsins (residues 1-326), four arrestins (residues 12-361 with a small missing loop of residues 340-342), and three T4Ls (residues 2-161 in complexes A and D; residues 2-12 and 58-162 in complex C; no T4L was modelled in complex B owing to poor density) (Fig. 2) . The final structure was refined to R work and R free of 25.2% and 29.3%, respectively, with excellent geometry (Supplementary Table 1b ). The overall arrangement of the T4L-rhodopsin-arrestin complex is well supported by the electron density maps (Extended Data Fig. 3) , including a 3,000 K simulated annealing omit map. Because of the twinned nature of the data sets, we performed extensive structure-validation experiments, including DEER, HDX, cell-based rhodopsin-arrestin interaction assays and site-specific disulfide cross-linking. Below we describe the rhodopsinarrestin structure and the results of validation experiments.
Overall structure of the rhodopsin-arrestin complex
The most striking feature of the rhodopsin-arrestin complex is the asymmetric binding of arrestin to rhodopsin (Fig. 2) and this asymmetric arrangement is similar in all four complexes in the asymmetric unit, providing an independent confirmation of the rhodopsinarrestin complex assembly (Extended Data Fig. 4 ). Figure 2a shows one rhodopsin-arrestin complex in four 90u orientations. From the intracellular (IC) view, rhodopsin and arrestin have similar heights, but the width of arrestin is nearly three times that of rhodopsin. Figure 2b shows the rhodopsin-arrestin complex in a transparent surface, whose overall arrangement of the domains can be fit into the electron microscopy images (Fig. 1e) . Figure 2c shows the layered or type I packing of the complex in the crystal lattice with alternating hydrophilic and hydrophobic layers comprising arrestin, T4L and rhodopsin, respectively (Fig. 2c) . This arrangement allows the complex to form extensive packing interactions that involve all soluble portions of the proteins, with the arrestin being the central mediator for packing with T4L, rhodopsin and arrestin from neighbouring symmetry-related molecules.
To validate the assembly of the rhodopsin-arrestin complex, we used DEER to determine intermolecular distances within the complex 40 . The DEER distances from residue Y74 2.41 of rhodopsin to three arrestin residues (T61, V140, and S241) measured in a non-fused rhodopsin-arrestin complex were 28 Å , 23 Å and 33 Å , closely matching the distances of 28 Å , 22 Å and 34 Å , respectively, as observed in the crystal structure (Fig. 3) . The intramolecular distances in the active arrestin bound to light-activated phosphorylated rhodopsin have also been studied extensively by DEER 41 , and all of them match exceedingly well with the crystal structure (Supplementary Table 3 ). Together, these data support the conclusion that the complex formed by fusion proteins closely resembles the physiologically relevant complex formed by individual proteins.
The rhodopsin-arrestin interface
The four rhodopsin-arrestin complexes in the asymmetric unit adopt nearly identical interfaces (Extended Data Fig. 4a ), which are stabilized by intermolecular interactions as summarized in Supplementary  Table 4 . The total surface area buried in the interface is 1,350 Å 2 , which is substantially smaller than the area (2,576 Å 2 ) buried in the b 2 AR-G s complex 8 . Unlike the continuous interface observed in the b 2 AR-G s complex, the rhodopsin-arrestin complex has four distinct 
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arrestin interface patches (Fig. 4a, b and Extended Data Fig. 4b ). The first arrestin interface patch consists of the finger loop (residues Q70 to L78), which adopts a short a-helix and forms extensive interactions with the C terminus of TM7 and the N terminus of helix 8, as well as the loop residues (ICL1) of rhodopsin (Fig. 5a ). Interactions of arrestin with TM7 of rhodopsin are of particular interest because conformational changes in TM7 have been implicated in arrestinbiased signalling 14, 15 . Moreover, the close interactions between rhodopsin's helix 8 and arrestin have been shown to be essential for high-affinity binding of arrestin to the activated rhodopsin 42 . The second arrestin interface patch is formed by the middle loop (residue V140 region) and the C-loop (residue Y251 region at the central loop in the arrestin C domain) that interact with the ICL2 of rhodopsin, and the arrestin back loop (R319 and T320) that interacts with the C terminus of TM5. The middle and C-loops are close to each other in the inactive arrestin, but move apart upon its activation to form a cleft that accommodates the ICL2 of rhodopsin, which adopts a short helix (Fig. 4a, b) . The positions of the finger loop and the C-loop are supported by a composite omit 2F o 2 F c electron density map (Extended Data Fig. 3a, d ). The third arrestin interface patch is the b-strand (residues 79-86), which follows the finger loop and interacts with residues from TM5, TM6 and ICL3 of rhodopsin. The fourth arrestin putative interface patch is mostly between its N-terminal b-strand (residues 11-19) and the C-terminal tail of rhodopsin, which was not visible in the electron density map owing to the apparent flexibility of this region, but was computationally modelled based on HDX and disulfide cross-linking data described below (Extended Data Fig. 5 ). Consistent with the crystal structure, these arrestin elements have been implicated in various aspects of arrestin activation and receptor binding 43, 44 . To further characterize the rhodopsin-arrestin interfaces, we performed three additional sets of validation experiments. The first was HDX, which probes the dynamics and stability of protein complexes 45 . Compared with free arrestin, the rhodopsin-bound arrestin has several regions that are protected from exchange, including the finger loop and the N-terminal b-sheets, consistent with their location in the rhodopsin-binding interface (Fig. 4c, d and Extended Data Fig. 6a ). The hydrogen to deuterium exchange rate of arrestin in the complex is lower than that for free arrestin across the whole protein, indicating that arrestin is stabilized by complex formation, consistent with the results of previous HDX experiments 46 and thermal stability assays, which revealed that the melting temperature of free arrestin is six degrees lower than that of the complex (53 uC versus 59 uC, Extended Data Fig. 6b) .
The second set consisted of Tango assays 47 , which have been used for probing GPCR-arrestin interactions (Extended Data Fig. 7a ). Wild-type rhodopsin and wild-type arrestin had a very low basal interaction and all-trans-retinal increased the binding by approximately threefold. In contrast, E113 Fig. 7b ). Correspondingly, mutations in rhodopsin residues involved in arrestin binding also weakened the interaction (Extended Data  Fig. 7c) , consistent with the complex crystal structure.
The third set consisted of site-specific disulfide cross-linking experiments, which have been used to validate structures based on the geometry requirements for disulfide bond formation (Ca-Ca 
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G2015 Macmillan Publishers Limited. All rights reserved distances of 5-9Å and appropriate side-chain orientations). We engineered cysteine pairs at the binding interface of arrestin and rhodopsin, which were tagged with Flag and HA, respectively. Over 314 co-expression combinations were tested and monitored by SDS-PAGE followed by western blotting (Extended Data Fig. 8 ). The results are summarized in Supplementary Table 5 . Every interface residue in arrestin was included in the study and the results closely agree with the crystal structure. For example, the distances from the Ca atom of the finger loop residue G77 of arrestin to the Ca atoms of N310 7.57 , K311 8.48 and Q312 8.49 in rhodopsin fit the requirement for disulfide bond formation (Fig. 5a ). G77C cross-linked efficiently with N310 7.57 C and Q312 8.49 C, but not with K311 8.48 C because the Cb of K311 8.48 points away from G77 ( Fig. 5a ). Neither did G77C show cross-linking with a large set of other rhodopsin residues, indicating the high specificity of the cross-linking experiments (Extended Data Fig. 8c and Supplementary Table 5 ). In contrast, several other mutants in the finger loop region (D74C, M76C, and L78C) readily crosslinked with Q312
8.49 C from helix 8 (Fig. 5a ). The cross-linking results of these four finger loop residues not only matched the crystal structure, but also agreed well with the results from the Tango assays (Extended Data Fig. 7b ). In addition, mutants of three N-terminal finger loop residues (Q70C, E71C, and D72C) were cross-linked to mutants in rhodopsin ICL1 T70 ICL1 C and K67 ICL1 C, respectively (Extended Data Fig. 7d ).
We also observed cross-linking of the arrestin middle loop (D139) with rhodopsin ICL2 (G149 ICL2 ) ( Fig. 5b) , of the arrestin C-loop (Y251) with rhodopsin TM5 (T229 5.64 and A233 5.68 ) (Fig. 5c) , and of the arrestin b-strand (residues 79-86) that follows the finger loop with rhodopsin TM5, TM6, and ICL3 (Fig. 5d) . Additional crosslinking was observed in two back-loop residues R319C and T320C of arrestin with Q237 ICL3 C of TM5 in rhodopsin (Extended Data Fig.  8e ). Furthermore, extensive cross-linking of the arrestin N terminus with the C-terminal tail of rhodopsin was detected, including R19 of arrestin with S334
Cterm of rhodopsin ( Fig. 5e ), K16 of arrestin with S338
Cterm and K339 Cterm of rhodopsin, and V11 and S10 of arrestin with the final eight residues of rhodopsin (Supplementary Table 5 ). Together, these cross-linking experiments further validated the interface assembly of the rhodopsin-arrestin complex.
Possible structural mechanisms for biased signalling
The rhodopsin-arrestin complex represents the first crystal structure of a GPCR bound to arrestin and provides an opportunity to examine the mechanism of arrestin-biased signalling. Although a crystal structure of G protein-bound rhodopsin is not available, several structures of rhodopsin bound to GaCT and analogue peptides have been determined 11, 22, 23, 39 and reveal that the arrangement of TM helices in lightactivated rhodopsin is similar to that in the G-protein-bound b 2 AR complex, with the exception of TM6, whose outward movement in b 2 AR is much more pronounced upon binding to G protein 8 . The arrestin-bound rhodopsin has its intracellular end of TM6 moved outward by approximately 10 Å relative to its inactive structure (Fig. 6a, b and Extended Data Fig. 9 ). This is in contrast to the 14 Å outward movement of TM6 reported in the G-protein-bound b 2 AR complex 8 . Compared to the active conformation of rhodopsin bound to GaCT peptides 11,22,23,39 , arrestin-bound rhodopsin has additional conformational differences in TM1, TM4, TM5, and TM7 (Fig. 6c, d and Extended Data Fig. 9 ), and these unique structural features may constitute essential elements for arrestin-biased signalling.
The molecular assembly observed in the rhodopsin-arrestin complex also provides a general model for arrestin recruitment by phosphorylated rhodopsin-like class A GPCRs. In the computational model of the full complex, the highly cationic N-terminal domain of arrestin is paired with the C-terminal tail of rhodopsin (Extended Data Fig. 10 ). Based on the extensive disulfide crosslinking data and computation modelling, phosphorylated S334, S338 and S343 can form tight ionic interactions with three positively charged pockets at the N terminus of arrestin (Extended Data Fig. 11a-d) . These results support a model of arrestin activation by phosphorylated rhodopsin through the C-tail exchange mechanism ( Fig. 6e) 2 . The displacement of the arrestin C terminus by the phosphorylated rhodopsin C-tail destabilizes the polar core of arrestin 48 , thus allowing for a 20u rotation of the N-and C-domains of arrestin that opens a cleft between the middle and C-loops into which the ICL2 helix of rhodopsin can fit. The ionic interaction between rhodopsin and arrestin is consistent with the fact that it is highly salt sensitive in our AlphaScreen assay (Extended Data Fig. 11e ), in agreement with the salt-sensitive binding of phosphorylated rhodopsin to arrestin 43, 48 . Importantly, the cytoplasmic face of the rhodopsin TM bundle is highly positively charged, whereas the finger loop (residues 70-78) contains three conserved negatively charged residues (E71, D72, and D74) (Extended Data Fig. 10 ). Thus, the interaction of arrestin with the rhodopsin TM bundle is mediated not only by shape but also by charge complementarity. Arrestins are highly conserved with only four subtypes in vertebrates. In contrast, there are hundreds of GPCRs, with cytoplasmic interfaces that are mainly non-conserved. However, the positive charge property is a common feature on the cytoplasmic side of a number of GPCR structures (Extended Data  Fig. 12 ). Electrostatic interactions between arrestins and GPCRs Rho   E239  S240  T242  T243  A246   A233  Q237  S240  T243  N310   Q237  E239  S240  T242  A241  T243   Rho   D330  D331  E332  S334  A335  T336   V337  S338  S334  A335  T336   F148  G149  E150 ; arrestin C-loop residue Y251 with rhodopsin TM5 (c); arrestin b-strand interface residues with residues of rhodopsin TM5, ICL3, and TM6 (d); and arrestin's N terminus with rhodopsin's C-tail (e). Rhodopsin K311 is marked with a red asterisk and the side chain of arrestin M76 is shown in full from computation modelling of the full rhodopsin-arrestin complex, which was also used in panel e. Black asterisks, arrestin; arrowheads, rhodopsin/arrestin crosslinking adduct.
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may represent an adaptive mechanism for arrestins to pair promiscuously with the large number of GPCRs.
The asymmetric orientation of the bound arrestin with regard to the relative positions of its N-C domains in respect to the membrane has important implication in its binding to rhodopsin (Fig. 2a, b) . Such asymmetric assembly brings the arrestin C-domain towards the membrane, with the C-edge either being touched or embedded in the membrane layer (Extended Data Fig. 13 ). The C-edge is comprised of conserved hydrophobic residues (F197, F198, M199, F339, and L343). It has been puzzling why single alanine mutations at these residues would affect arrestin binding to rhodopsin given how far away they are from the receptor 43 . The close proximity of these hydrophobic residues to the membrane surface may provide an explanation for the effects of these mutations on rhodopsin binding. GPCR signalling regulator proteins are normally membrane-associated through lipid modifications, as is the case for GPCR kinase 1 (GRK1) and the G-protein subunits Ga and Gbc. Yet, there is no known lipid modification for any of the arrestins. We speculate that the conserved hydrophobic patch at the C-tip of arrestin may function as a lipidinteracting module that helps to stabilize its interaction with the receptor. Furthermore, one primary function of arrestin is to mediate endocytosis of ligand-activated GPCRs and the highly asymmetric nature of the rhodopsin-arrestin assembly may facilitate the membrane curvature for subsequent endocytotic processes. Alternatively, the remote C-tip could serve as the binding site of a second rhodopsin, which has been proposed to form dimers in the rod outer-segment disc membrane 49 . LCP-SFX is a new technology that has been used to determine several crystal structures 35, 36, 50 . Rhodopsin-arrestin is a challenging membrane protein complex and obtaining a structure of this complex at a sufficiently high resolution was an intractable task using existing methods that include synchrotron-based crystallography and cryoelectron microscopy 26 . The rhodopsin-arrestin complex structure reported here demonstrates the utility of X-ray lasers when combined with SFX and an LCP crystal delivery system 35 . The SFX method is relatively new and under continuous development. Given its success in solving the rhodopsin-arrestin structure, we expect that X-ray lasers, with further method development, will continue to provide breakthrough insights into biology and chemistry.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. In the dark state, the receptor is inactive (R-state) and arrestin is in the closed state (basal state). Receptor activation and phosphorylation (P-R* state) allow the phosphorylated C-terminal tail of rhodopsin to bind to the N-domain of arrestin (pre-activated state), thus displacing the arrestin C-terminal tail. This displacement destabilizes the polar core of arrestin, which allows a 20u rotation between the arrestin N-and C-domains, leading to the opening of the middle loop (ML) and C-loop (CL) to accommodate the ICL2 helix of rhodopsin (fully activated state). The activated receptor also opens the cytoplasmic side of the TM bundle to adopt the finger loop (FL) of arrestin. In this model, the tip of arrestin's C-domain contacts the membrane (red asterisk).
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METHODS
No statistical methods were used to predetermine sample size. Protein preparation. We used human rhodopsin and mouse visual arrestin-1 in this study. The T4L-rhodopsin-arrestin fusion protein was expressed using a tetracycline-inducible expression cassette encoding a fusion protein with His 8 -MBP-MBP followed by a 3C protease cleavage site at the N terminus of the T4L-rhodopsin-arrestin. In this engineered construct, we have fused a cysteine-free T4L (residues 2-161 with C54T and C97A) to the N terminus of a rhodopsin that contains four mutations: N2 Nterm C and N282 ECL3 C to form a disulfide bond, and E113 3.28 Q and M257 6.40 Y for constitutive receptor activity. The C terminus of rhodopsin was fused to 3A arrestin (L374A, V375A, F376A, residues 10-392) with a 15 amino acid linker (AAAGSAGSAGSAGSA).
The fusion protein constructs were expressed in HEK293S cells (Invitrogen) transiently transfected using Lipofectamine 2000 (Invitrogen). Cells were transfected at a density of 2 3 10 6 cells per ml at a 100 ml scale in SFM4TransFx-293 (HyClone). Six hours post-transfection, cells were diluted tenfold with CDM4HEK293 medium (HyClone). When the cell density reached approximately 4 3 10 6 cells per ml, protein expression was induced by the addition of doxycycline to a final concentration of 1 mg ml 21 . After 24 h induction, cells were harvested, resuspended in hypotonic buffer (20 mM HEPES-Na, pH 7.5, 10 mM NaCl, 10 mM MgCl 2 ) supplemented with EDTA-free protease inhibitor cocktail (Roche), followed by Dounce homogenization. The lysate was centrifuged at 45,000 r.p.m. at 4 uC for 1 h. The membranes were solubilized in 20 mM TrisHCl, pH 7.4, 100 mM NaCl, 10% glycerol, 0.5% (w/v) n-dodecyl-b-D-maltopyranoside (DDM, Anatrace), 0.1% (w/v) cholesteryl hemisuccinate (CHS, Anatrace), and protease inhibitor cocktail for two hours at 4 uC. The supernatant was isolated by centrifugation at 45,000 r.p.m. for one hour, and incubated with amylose beads (New England Biolabs) at 4 uC overnight. Typically 10 ml of resin were used for supernatant from one litre of the original cell culture. The resin was washed with 200 ml of washing buffer (10 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.005% (w/v) lauryl maltose neopentyl glycol (MNG-3, Anatrace), 0.001% (w/v) CHS) and the protein was eluted with washing buffer containing 10 mM maltose. The eluted fusion protein was concentrated to 40-50 mg per 1 ml and the His 8 -MBP-MBP tag was cleaved by overnight incubation with 3C protease at 4 uC. The cleaved His 8 -MBP-MBP tag was removed by incubating with 300 ml Ni 21 -NTA beads (Qiagen) for three hours at 4 uC. The purified T4L-rhodopsin-arrestin was collected and concentrated to 30 mg ml 21 for crystallization. Wild-type rhodopsin and rhodopsin mutants E113 Y used for MBP pull-down and AlphaScreen assays were expressed from the same vector with a His 8 -MBP tag at the N terminus. Protein expression and purification were similar as for the rhodopsin-arrestin fusion protein used for crystallization, with the difference that proteins were not eluted, but remained bound to beads.
To generate biotinylated proteins for the AlphaScreen assays, wild-type and 3A arrestin (residues 10-392) open reading frames were cloned with N-terminal avitag-MBP tag into the first expression cassette of a modified pET-Duet expression vector (Novagen), and the biotin ligase gene BirA was cloned into the second cassette. The 14 amino acid avitag contains a single lysine that is efficiently biotinylated in vivo by the BirA protein 51 . BL21 (DE3) cells transformed with the expression plasmid were grown in LB broth at 16 uC to an OD 600 of ,1.0 and induced with 0.1 mM IPTG in the presence of 40 mM biotin for 16 h. Cells were harvested, resuspended in 50 ml extraction buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 10% glycerol) per two litres of cells, and passed three times through a French Press with pressure set at 1,000 Pa. The lysate was centrifuged at 16,000 r.p.m. in a Sorvall SS-34 rotor for 30 min, and the supernatant was loaded on a 5 ml amylose HP column (GE Healthcare). The column was washed with 100 ml of wash buffer (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 10% glycerol) and eluted in buffer containing 20 mM Tris-HCl, pH 8.0, 150 mM NaCl and 20 mM maltose. The eluted biotin-MBP-arrestin was concentrated and further purified by size-exclusion chromatography through a HiLoad 16/60 Superdex 200 column (GE Healthcare) in 20 mM Tris-HCl, pH 8.0, and 150 mM NaCl. Monomeric protein was collected for further assay.
Untagged 3A arrestin (residues 10-392) was expressed as a His 6 -SUMO fusion protein from the expression vector pSUMO (LifeSensors). The expression and purification of untagged arrestin followed the same method as for biotin-MBParrestin, except that the His 6 -SUMO tag was cleaved overnight with SUMO protease 52 at a protease/protein ratio of 1:1,000 in the cold room. MBP pull-down assay. Arrestin was cloned into the pCITE-4a vector (Novagen) to allow for transcription from a T7 promoter. The TNT Quick Coupled Transcription and Translation kit was used according to the manufacturer's protocol (Promega), to express [ 35 S]methionine-labelled wild-type arrestin and 3A arrestin (L374A, V376A, and F376A). Radiolabelled wild-type arrestin and mutant arrestin proteins were incubated with His 8 -MBP-rhodopsin fusion protein immobilized to 50 ml of maltose agarose bead suspension. Proteins and beads were incubated at 4 uC for one hour on a rotating platform in binding buffer containing 20 mM Tris-HCl, pH 7.4, 100 mM NaCl and 0.02% DDM/0.004% CHS. The beads were then washed three times with binding buffer and resuspended in 400 ml elution buffer (20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.02% DDM/0.004% CHS and 100 mM maltose). The eluates were concentrated and incubated at room temperature for 15 min with 2 3 loading dye. Samples were separated on 12% sodium dodecyl sulfate (SDS)-denaturing polyacrylamide gels. Gels were stained with Coomassie R-250, dried at 70 uC for 90 min, and exposed overnight to a phosphor storage screen. Results were visualized on a PhosphorImager (Fuji). Assays for the interactions between rhodopsin and arrestin or G protein peptide. Interactions between rhodopsin and arrestin were assessed by luminescence-based AlphaScreen assay (Perkin Elmer), which our group has used extensively to determine ligand-dependent protein-protein interactions of nuclear receptors. The AlphaScreen principle is illustrated in Extended Data Fig. 1c . Briefly, biotinylated arrestin was bound to streptavidin-coated donor beads and His8-tagged rhodopsin was bound to nickel-chelated acceptor beads. The donor and acceptor beads were brought into close proximity by the interactions between rhodopsin and arrestin, which were measured in the presence or absence of alltrans-retinal (Sigma). When excited by a laser beam of 680 nm, the donor bead emits singlet oxygen that activates thioxene derivatives in the acceptor beads, which releases photons of 520-620 nm as the binding signal. The experiments were conducted with 100 nM of rhodopsin and arrestin proteins in the presence of 5 mg ml 21 donor and acceptor beads in a buffer of 50 mM MOPS-Na, pH 7.4, 50 mM NaF, 50 mM CHAPS, and 0.1 mg ml 21 bovine serum albumin. The results were based on an average of three experiments with standard errors typically less than 10%. GaCT-HA (TGGRVLEDLKSCGLF) and biotinylated GaCT-HA were synthesized by Peptide 2.0. For the competition assay, different amounts of untagged arrestin or GaCT-HA were added to the reaction to compete with tagged arrestin or GaCT-HA for rhodopsin binding. Thermal stability assay. The thermal stability assay was performed with the thiol-specific fluorochrome N-[4-(7-diethylamino-4-methyl-3-coumariny)phenyl]maleimide (CPM) as described previously 53 . Briefly, 10 mg of protein was diluted with dilution buffer (20 mM Tris-HCl, pH 7.5, 200 mM NaCl, 0.005% MNG-3/CHS) to 195 ml, while CPM dye stock (4 mg ml 21 in DMSO) was freshly diluted to 0.2 mg ml 21 in the dark. After 5 min of incubation at room temperature for both protein and CPM dye separately, 5 ml of diluted CPM dye was added to the protein sample and the protein/dye mix transferred immediately into a submicro quartz fluorometer cuvette (Starna Cells) and measured in a Cary Eclipse spectrofluorometer (Agilent). Assays were performed from 20 uC to 80 uC with a slope of 2 uC increase per minute at an excitation wavelength of 387 nm and an emission wavelength of 463 nm. All data were processed using GraphPad Prism and fit using the Boltzmann sigmoidal equation to determine the melting temperature (T m ) as inflection point of the melting curves. Crystallization. T4L-rhodopsin-arrestin crystals were grown in lipid cubic phase (LCP) 54 . Protein solution (,30 mg ml
21
) was mixed with monopalmitolein (9.7 MAG, from Nu-Chek Prep, Inc.) containing 10% cholesterol at a 1:1 ratio (w/w) using a coupled syringe mixer 55 and 50 nl boluses of protein-laden LCP were dispensed on 96-well glass sandwich plates (Molecular Dimensions or Marienfeld-Superior) and overlaid with 0.8 ml precipitant solutions using a Gryphon LCP robot (Art Robbins Instruments) or an NT8-LCP robot (Formulatrix). Multiple initial hits were identified by using screens of 30% PEG 400 in combination of 100 mM or 400 mM salts from the StockOptions Salt kit (Hampton Research) 56 . Crystals that reached full size (around 10-20 mm) within four days at 20 uC were harvested from the mesophase and were flash frozen in liquid nitrogen without additional cryoprotectant. Crystals used for synchrotron data collection were grown in 0.05 M magnesium acetate, 0.05 M sodium acetate, pH 5.0 and 28% PEG 400.
Crystals for LCP-SFX were prepared in 100 ml gas-tight Hamilton syringes as described 36, 57 . About 5 ml of protein-laden LCP in the presence of fivefold molar excess of all-trans-retinal was slowly injected into 60 ml mother liquid buffer (0.15 M ammonium phosphate, pH 6.4 and 32% PEG 400) using a coupled syringe mixing device 55 . Crystals were grown in several syringes at 20 uC, consolidated and transferred into the LCP injector 35 for XFEL diffraction data collection. The average crystal size was 5-10 mm as determined under a polarized light microscope. The phase diagram for 9.7 MAG suggests that this MAG is a suitable host lipid for extruding LCP in vacuum at 20 uC, where evaporative cooling created problems when 9.9 MAG was used as a host LCP lipid 35 . Data collection (synchrotron). A partial 8.0 Å synchrotron data set was collected at 100 K using an X-ray beam at the wavelength of 1.0 Å at the 21 ID-D beam line of LS-CAT and at 23-ID-D of GM-CAT at the Advanced Photon Source at RESEARCH ARTICLE Argonne National Laboratory. A full 7.7 Å data set was collected from a single crystal (,20 mm in size) using 10 mm beam size and 0.1 s exposures per 0.1u oscillation with a Pilatus 6M pixel detector at the X10SA beam line at the Swiss Light Source. The observed reflections were reduced, merged, and scaled with XDS 58 with statistics shown in Supplementary Table 1a . The L-test plot of the 7.7 Å data set is consistent with a perfectly twinned crystal. Data collection (XFEL). LCP-SFX experiments were carried out at the Coherent X-ray Imaging (CXI) instrument 59 at the Linac Coherent Light Source (LCLS) in the SLAC National Accelerator Laboratory (Menlo Park, California, USA). X-ray pulses of 50 fs duration at a wavelength of 1.3 Å (9.5 keV) were attenuated to ,3% (3 3 10 10 photons per pulse) and focused to ,1.5 mm diameter at the interaction point using Kirkpatrick-Baez mirrors 60 . Rhodopsin-arrestin complex crystals in LCP were injected across the XFEL beam using an LCP injector 35 with a 50 mm diameter nozzle at a flow rate of ,0.2 ml min
. Diffraction patterns were collected at 120 Hz using the Cornell-SLAC Pixel Array Detector (CSPAD). Over 5 million data frames were collected corresponding to ,12 h of data acquisition time. Of these frames, ,0.45% images contained potential crystal hits as identified using Cheetah 61 (more than 40 Bragg peaks of 1-20 pixels in size and a signal to noise ratio better than 6 after local background subtraction). Of the potential crystal hits, 18,874 diffraction patterns could be auto-indexed by CrystFEL 38 using a combination of MOSFLM 62 , XDS 58 and DirAx 63 . An integration radius of only two pixels was used to avoid overlapping with neighbouring peaks due to the high spot density resulting from the large unit cell dimensions. Partial reflections from different crystals in random orientations were merged using a Monte Carlo integration across the crystal rocking curve of each reflection 64 . The resolution was anisotropic with ,3.3 Å resolution along the c*-axis and ,3.8 Å resolution along the a*/b* axes. The data used for the structure refinement were truncated at 3.8 Å /3.8 Å /3.3 Å using the get_hkl program of CrystFEL 38 based on the criteria of data correlation coefficient (CC*), which is 0.87 at the highest resolution shell (Supplementary Table 1a) . The use of CC* of 0.5 as resolution cutoff has been recently recommended for X-ray diffraction 65 . The resolution cutoff for several published XFEL structures follows this criterion, including the 5HT 2B GPCR XFEL structure 36 , which has a CC* of 0.74. The statistics of the final data used in structure refinement are shown in Supplementary Table 1b . Structure determination. The XFEL data were initially merged according to the apparent Laue group of 4/mmm, and molecular replacement searches were performed in all possible space groups of 4/m and 4/mmm. The best structure solution was found in P4 3 . Based on analysis of the Zanuda program 66 , we determined that the most likely space group was P2 1 2 1 2 1 and that the crystals were physically twinned. The data were reprocessed with the Laue group of mmm and molecular replacement searches were performed in P2 1 2 1 2 1 . This space group assignment resulted in the best statistics and map quality out of several possible space groups (Supplementary Table 2 ).
The crystals appeared to be pseudo-merohedrally twinned based on L-test analysis 67 . Despite the challenge of twinned data, the rhodopsin-arrestin complex structure was solved by the molecular replacement method implemented in Phaser 68 using the models of constitutively active rhodopsin, pre-activated arrestin, and T4L (PDB codes: 4A4M 39 , 4J2Q 1 , and 3SN6 8 , respectively). Four molecules of rhodopsin and four molecules of arrestin were found sequentially by molecular replacement search, resulting in four very similar rhodopsin-arrestin assemblies. Four T4Ls were also found in the aqueous layer with its C-terminal residue in a position to form a covalent bond with the first residue of rhodopsin, supporting the correct positioning of T4Ls by molecular replacement.
The structure was initially refined against the XFEL data without twin law to an R free -factor of ,36% and the model maps from the data were of sufficient quality to interpret the overall structure of the rhodopsin-arrestin complex (Extended Data Fig. 3) . The model then underwent iterated cycles of manual building into 2F o 2 F c maps with Coot 69 and refinement with REFMAC 70 and the PHENIX 71 , where rigid body, individual position, group B-factor, and TLS refinements were used along with NCS restraints and twin law (k, h, -l). The arrestin residues 70-78 and 165-175, which were not included in the molecular replacement model, were manually placed into the density map. These two regions of arrestin became visible because they are either engaged in direct interaction with rhodopsin or involved in crystal packing. Regions with poor density were removed from the final model, including T4L from the B complex and the N-domain of T4L (residues 13-57) from the C complex. We did not observe clear electron density for the all-trans-retinal, which was thus not included in the structure. The structure has been carefully refined to the final state that has excellent geometry and refinement statistics (Supplementary Table 1b) . Ramachandran plot analysis indicates that 100% of the residues are in favourable or allowed regions (no outliers). The final structure was validated with MolProbity, which revealed an all-atom-clash score of 1.47 and MolProbity score of 1.13 72 .
The real-space correlation coefficients against a 2mF o 2 DF c map for each chain of the structure on a per residue basis using the CCP4 EDSTATS program 73 or the MolProbity program in Phenix indicated an overall good fit between the structure and the electron density map. The density fit correlation in Coot was low with the structure from Phenix twinned refinement because the map from the MTZ file with map coefficients produced by phenix.refine was not in absolute scale. This problem was overcome by using the 2F o 2 F c CNS format map from phenix.refine, which generated a normal correlation in Coot, similar to those from EDSTATS and MolProbity. All structural figures were prepared using PyMOL 74 . Cell-based assays for rhodopsin-arrestin interactions (Tango assays). For the cell-based Tango assay 47 , we generated fusion constructs consisting of rhodopsin (1-321), a tobacco etch virus (TEV) protease cleavage site (TEV site), and the transcriptional activator tTA (Rho-TEV site-rTA) as well as of arrestin (10-392) and TEV protease (Arr-TEV protease). HTL cells were a gift from G. Barnea and R. Axel (Brown University and Columbia University). 10 ng Rho-TEV site-tTA construct were transfected together with 10 ng Arr-TEV protease plasmid and 1 ng of phRG-tk Renilla luciferase expression vector into HTL cells using Xtremgene (Roche). One day after transfection, cells were induced by vehicle (DMSO) or all-trans-retinal (10 mM) overnight. Cells were harvested and lysed in Passive Lysis Buffer (Promega). Luciferase activity was measured using the Dual Luciferase Kit (Promega) according to manufacturer's instructions. Mutagenesis. Site-directed mutagenesis was carried out using the QuikChange method (Agilent). Mutations and all plasmid constructs were confirmed by sequencing before protein expression, MBP-pull down assay, Tango assay, and AlphaScreen assay. Electron microscopy studies of the rhodopsin-arrestin complex. Samples were prepared as previously described 75 . Briefly, the sample was applied to a freshly glow-discharged carbon coated copper grid and allowed to adhere for 10 s before being reduced to a thin film by blotting. Immediately after blotting 3 ml of a 1% solution of uranyl formate was applied to the grid and blotted off directly. This was repeated three times. Data were acquired using a Tecnai F20 Twin transmission electron microscope operating at 200 kV, with a dose of ,40 e 2 Å 22 and nominal underfocus ranging from 2 to 3 mm. Images were automatically collected at a nominal magnification of 62,000 3 and pixel size of 0.273 nm. All images were recorded with a Tietz F416 4k 3 4k pixel CCD camera using Leginon data collection software 76 . Experimental data were processed by the Appion software package 77 , which interfaces with the Leginon database infrastructure. ,6,000 particles were automatically extracted from 54 electron microscopy micrographs 78 and the particle stack was then aligned and sorted using the XMIPP reference-free maximum likelihood alignment 79 . Several exemplary 2D averages are shown in Fig. 1e , which were derived from class averages for the complex with or without T4L, computed from ,14,000 particles selected from 155 electron microscopy-micrographs. In-cell disulfide bond cross-linking. The open reading frames of full-length arrestin with C-terminal Flag tag and full-length rhodopsin with C-terminal haemagglutinin (HA) tag were cloned into pcDNA6. Cysteine mutations (41 for arrestin and 51 for rhodopsin) were systematically introduced into arrestin and rhodopsin in these two DNA vectors. AD293 cells were split one day before transfection at 50,000 cells per well in a 24-well plate. Cells were grown for one day, then transfected with 100 ng rhodopsin constructs (pcDNA6-rho-3HA) plus 100 ng arrestin plasmid (pcDNA6-Arr-3Flag) by Lipofectamine 2000 (DNA/Lipofectamine 2000 ratio of 1:2) in each well. Cells were grown for 2 days after transfection, and were then treated at room temperature with H 2 O 2 , which was freshly diluted in the cell culture medium to a final concentration of 1 mM. After 5 min treatment with H 2 O 2, the medium was aspirated and 100 ml of CelLytic M (Sigma C2978) were added to each well and the plate was shaken for 10 min at room temperature. Cell lysates were transferred to 1.5 ml tubes and spun at 16,000g at 4 uC for 5 min. The supernatants (10 ml) were mixed with an equal volume of 2 3 SDS loading buffer (without reducing agents) for 5 min at room temperature, and loaded onto a protein gel for western blot analysis. Horseradish peroxidase-conjugated anti-Flag (Sigma M2) and anti-HA (Sigma) antibodies were used to probe for free and cross-linked arrestin and rhodopsin proteins. Hydrogen-deuterium exchange mass spectrometry (HDX). HDX was carried out as described previously 80 , with the following modifications: (1) the solution handling and mixing was performed with a LEAP Technologies Twin HTS PAL liquid handling robot housed inside a temperature-controlled cabinet held at 4 uC and (2) decyl maltose neopentyl glycol (DMNG) was used in place of DDM in the exchange buffer. Briefly, all stock solutions and dilutions were made using the 7TM HDX buffer (50 mM HEPES (pH 7.5), 150 mM NaCl, 2% (v/v) glycerol, 0.01% (m/v) CHS and 0.05% (m/v) DMNG in either H 2 O or in D 2 O for onexchange). All HDX protein stock solutions were prepared at 15 mM in the 7TM
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HDX H 2 O buffer. On-exchange was carried out in triplicate for predetermined times (10, 30, 60, 900 and 3,600 s) at 4 uC by mixing 5 ml of stock protein solution with 20 ml of D 2 O on-exchange buffer. Exchange was quenched by adding 25 ml of quench solution (100 mM NaH 2 PO 4 , 0.02% DMNG, and 15 mM TCEP at pH 2.4) to the reaction. Digestion was performed in line with chromatography using an in-house packed pepsin column. Peptides were captured and desalted on a C8 trap. Peptides were then separated across a 5m 10 3 1 mm Betasil C8 column (Thermo Fisher Scientific) with a linear gradient of 12-40% acetonitrile in 0.3% formic acid over a short 5 min gradient to limit back exchange with the solvent.
Mass spectra were acquired in the range of m/z 300-2,000 at a resolution of 60,000 for 8 min in positive ion mode on a Q Exactive mass spectrometer (Thermo Fisher Scientific) equipped with an ESI source operated at a capillary temperature of 225 uC and spray voltage of 3.5 kV. The intensity weighted average m/z value (centroid) of each peptide's isotopic envelope was calculated with the Workbench program 81 and converted to % deuterium values. Back-exchange correction was based on an estimated 70% deuterium recovery and accounting for the known 80% deuterium content of the on-exchange buffer. The Workbench software used P values lower than 0.05 for two consecutive time points to determine significance. Sequence coverage experiments for these proteins were carried out in the 7TM HDX buffer and LC system described above, but with a longer 60 min gradient. 75 pmol of protein were loaded onto the column. For sequencing, tandem mass spectra were obtained using data-dependent acquisition with 30 s dynamic exclusion, where the top five most abundant ions in each scan were selected and subjected to CID fragmentation. Each scan was the average of 3 microscans under normal scan mode in both MS and MS/MS. Peptides were identified by searching spectra against an in-house database using the mascot search engine as described previously 45 . Generation of a stable cell line expressing bovine rhodopsin mutant Y74C/ C140S/C316S and rhodopsin preparation. The rhodopsin mutant Y74C/ C140S/C316S gene 82 was PCR-amplified from the pMT vector by using two flanking primers containing NheI and NotI restriction sites and subcloned into vector PB-T-PAF 83 . The insert in the resulting plasmid termed PB-Rho-Y74C was verified by automated DNA sequencing.
Generation of the stable cell line as well as rhodopsin production and purification was performed as described 84 . HEK293S GnTI 2 cells 85 were cultured in DMEM/F12 (Wisent) supplemented with 10% heat inactivated FBS (Life Technologies) and 100 U ml 21 penicillin/streptomycin (Life Technologies) and incubated at 37 uC, 5% CO 2 . For transfection, cells were plated in 6-well plates at a density of ,600,000 cells per well. The following day, cells were co-transfected with 4 mg of PB-Rho-Y74C, 0.5 mg of PB-RB 83 and 0.5 mg of pCyL43 83, 86 using JetPrime (PolyPlus, France) reagent following the manufacturer's instructions and medium was replaced by fresh medium 4 h later. (Plasmids PB-T-PAF and PB-RB were provided by James Rini, University of Toronto, Canada, and pCyL43 by the Wellcome Trust Sanger Institute, UK). Two days after transfection, cells were transferred to a 100-mm tissue culture plate. Dual drug selection was started the following day, using 10 mg ml 21 puromycin (Bioshop, Canada) and 5 mg ml 21 blasticidin (Bioshop, Canada) and lasted for 2 weeks. Cells were then transferred to larger flasks and finally to pleated roller bottles (Thermo Scientific, USA) containing 250 ml of DMEM/F12 supplemented with 10% heat-inactivated FBS and 100 U ml 21 of penicillin and 100 mg ml 21 streptomycin. Roller bottles were incubated at 37 uC, 5% CO 2 and rotated at 0.1 r.p.m. Expression was induced after 5-6 days by replacing medium with 250 ml of fresh medium containing 1 mg ml 21 doxycycline (Bio Basic) and 1 mg ml 21 aprotinin (Bioshop Canada). On day 3 after induction, cells were harvested, using PBS-EDTA with protease inhibitor tablet (Roche) to detach cells. Cell pellets were flash frozen in liquid nitrogen and stored at 280 uC until purification.
For purification, cell pellets with rhodopsin mutant Y74C/C140S/C316S were incubated with 11-cis retinal to reconstitute rhodopsin which was purified and spin labelled with 1-oxyl-2,2,5,5-tetramethyl-3-pyrroline-3-methyl methanethiosulfonate (MTSSL) as previously described 41 . Incorporation of spin labelled rhodopsin into nanodiscs. Nanodiscs were prepared by mixing cholate solubilized lipid (70% POPC 1 30% POPS), scaffolding protein MSP1E3D1 87 , and rhodopsin (in 90 mM b-OG) in a molar ratio of 140:1:0.1. The OG and cholate were removed from the mixture by dialysis against buffer D (20 mM MOPS, 150 mM NaCl, pH 6.8). The nanodiscs were further purified by passing them over a nickel NTA column to remove any receptor not incorporated into the discs. Upon elution from the nickel column with imidazole, the nanodiscs were buffer exchanged into buffer D containing 10% glycerol. Spin labelling of arrestin mutants. C-terminally truncated mutants of arrestin, lacking endogenous cysteines, have been shown to bind to non-phosphorylated rhodopsin 88 . Single-cysteine mutants in this background were expressed in E. coli, as described 89 , spin labelled in buffer D overnight using a tenfold molar excess of MTSSL. The base mutant also contained two alanine substitutions (F85A and F197A) which have been shown to disrupt arrestin-1 oligomerization 89 . Noncovalently bound spin label was removed from the sample by extensive washes with buffer D using Amicon 10 kDa concentrators. DEER spectroscopy of the rhodopsin-arrestin complex. Preparations of rhodopsin (Y74 2.41 C) and bovine arrestin (S60C, V139C, and L240C, which correspond to the mouse arrestin T61C, V140C, and S241C) and their spin labelling were performed as described previously 41 . For DEER measurements, the spinlabelled proteins were mixed in 1:1 ratio in the dark and loaded into quartz capillaries (1.5 mm internal diameter and 1.8 mm outer diameter). The samples were irradiated for 30 s within the capillaries using a tungsten light source with a 500 nm cutoff filter. Immediately after irradiation, the samples were flash frozen in liquid nitrogen, and loaded into an EN 5107D2 resonator for Q band DEER measurements. Measurements were performed at 80 K on a Bruker Elexsys 580 spectrometer with a Super Q-FTu Bridge. A 36-ns p-pump pulse was applied to the low field peak of the nitroxide field swept spectrum, and the observer p/2 (16 ns) and p (32 ns) pulses were positioned 50 MHz (17.8 G) upfield, which corresponds to the nitroxide centre line. Model-free distance distributions were obtained from the raw dipolar evolution data using the LabVIEW (National Instruments) program ''LongDistances'' that can be downloaded from http:// www.biochemistry.ucla.edu/biochem/Faculty/Hubbell/.
To estimate the median distances, the distance distributions were integrated and normalized to the maximum amplitude. The median distance was estimated as that corresponding to 0.5 of the integrated intensity. The modelled distances between nitroxide spin labels are based on the crystal structure of the rhodopsinarrestin complex. R1 nitroxide side chains were modelled into the structure using common R1 rotamers 90, 91 . 9.7 MAG/water temperature-composition phase diagram. The phase diagram was constructed based on small-and wide-angle X-ray scattering measurements made in the heating direction. Sample preparation and X-ray scattering measurements and analysis were as previously described 55, 92 . The phases identified include the lamellar crystalline (Lc) or solid phase, the fluid isotropic (FI) or liquid phase, and the following liquid crystalline phases: lamellar liquid crystal (L a ), cubic-Ia3d and cubic-Pn3m. A separate aqueous phase observed in equilibrium with the solid or liquid crystalline phases is indicated by Aq. The phase diagram shows that the solid Lc phase stabilizes under equilibrium conditions below ,8 uC. The latter is some 10 uC below that observed with 9.9 MAG (monoolein) 92 and is similar to what was found with 7.9 MAG 93 . This low solidification temperature enabled use in the current project of 9.7 MAG as the host lipid for LCP-SFX data collection in an evacuated sample chamber at 20 uC, where evaporative cooling created problems for measurements with 9.9 MAG but not with 7.9 MAG
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. The maximum water carrying capacity of 9.7 MAG resides at ,50%(w/w) water, which is considerably greater and smaller than that of 9.9 MAG 92 and 7.7 MAG 94 , respectively. These observations indicate that the cubic mesophase of 9.7 MAG has larger aqueous channels compared to 9.9 MAG that are more like those of 7.7 MAG. This is consistent with 9.7 MAG supporting the growth of rhodopsin-arrestin-T4L crystals where the complex has sizable extra-membrane bulk best accommodated in a large aqueous channel. This parallels the rational use of 7.7 MAG as a host lipid for the b 2 AR-Gs complex crystallization and structure determination 8 . Molecular modelling of the full-length rhodopsin-arrestin complex. Energybased conformational modelling of the rhodopsin-arrestin complex was performed with the ICM-Pro molecular suite 95 , using a global energy optimization procedure similar to the one described recently for modelling of the full-length complex of CRFR1 96 . Protein sequences of human rhodopsin and mouse arrestin were obtained from the Uniprot database (http://www.uniprot.org/). Starting from the crystallographically determined structure of the complex, the modelling procedure was used to add unresolved residues of the C terminus (residues 327-345) of the human rhodopsin structure, as well as missing residues in the arrestin loop (residues 340-342) of the mouse arrestin structure. The final model did not include the last 3 residues of rhodopsin (346-348), which lack well-defined crosslinking contacts and appear flexible. Initial conformations of the short loop in arrestin were predicted with the fast ''build model'' ICM algorithm, followed by extensive energy optimization in internal coordinates. Conformational optimization of the rhodopsin C-terminal peptide was guided by soft pairwise harmonic distance restraints derived from disulfide crosslinking data. The restraints introduced between Cb atoms of the crosslinked residues were graded according to the crosslinking strength listed in Supplementary Table 5 , from very strong, with the penalty function starting at 5 Å distance, to medium at 7 Å distance and very weak at 12 Å . The C-terminal peptide conformation and conformation of the contact side chains of the arrestin were optimized to convergence (3 independent simulations of 10 6 steps) using global optimization procedure in internal coordinates with improved conformational energy terms for protein and peptides 97 . A special RESEARCH ARTICLE backbone closure sampling procedure was applied to the loop regions to allow efficient optimization. The global optimization runs were executed in parallel on a Linux multicore server resulting in similar best energy conformations (,3 Å r.m.s.d.; root mean squared deviation) for the C-terminal peptide residues. The best energy-optimized conformation of this region suggests that the extended C terminus peptide runs antiparallel along the N-terminal b-strand of arrestin. This conformation of the C terminus satisfied all 17 medium to strong disulfide crosslinking restraints for this region (Supplementary Table 5 ), while making a number of specific polar interactions and salt bridges of D331, E332 and E341 side chains with arrestin basic residues (Extended Data Fig. 5 ). These modelling results suggest that although the rhodopsin C terminus is rather flexible, some low energy conformations may be preferable even in non-phosphorylated rhodopsin. Moreover, independent modelling of the complex with phosphorylated serine residues Ser334, Ser338 and Ser343 in the C terminus of rhodopsin resulted in a similar conformation of this domain. The interactions within phosphorylated complex, however, are greatly enhanced by as many as seven additional salt bridges between negatively charged phosphates and the positively charged lysine and arginine residues within the N-terminal domain of arrestin (Extended Data Fig. 11 ). and the key interfaces based on the XFEL data. a, A 2F o 2 F c electron density map contoured at 1s of the arrestin finger loop, which forms the key interface with TM7 and helix 8. b, A 2F o 2 F c electron density map contoured at 1s of the loop between TM5 and TM6, which forms the key interface with the b-strand following the finger loop. c, A 3,000 K simulated annealing omit map (2F o 2 F c electron density map contoured at 1s) calculated from the 3.8 Å /3.8 Å /3.3 Å XFEL data supports the overall arrangement of the rhodopsin-arrestin complex. In all panels, the complex structure is shown with rhodopsin coloured in green and arrestin in brown. d, The C-loop with a 2F o 2 F c composite omit map at 1s calculated from the 3.8 Å /3.8 Å /3.3 Å truncated XFEL data. Key residues are labelled. linking specificity. a, The product of the cross-linking reaction of finger loop residue G77C with N310 7.57 C of TM7 was confirmed by western blots using anti-Flag antibody (which detects arrestin-Flag fusion) and anti-HA antibody (which detects rhodopsin-HA fusion). The cross-linked products are marked with arrow heads, and free-arrestin and free-rhodopsin are indicated by asterisks. Arrestin (3A) and rhodopsin (4M) without cysteine mutations do not form cross-linked products. b, The cross-linked product of finger loop residue G77C with N310 7.57 C of TM7 was sensitive to treatment with reducing agents, indicating the cross-linking is mediated through disulfide bond formation. c, A close-up view of arrestin finger loop residues M76C and G77C and their cross-linking with rhodopsin, which shows that G77C was specifically cross-linked to N310 C of helix 8, but not to other residues. d, Structure and cross-linking of finger loop N-terminal residues Q70C, E71C, and D72C of arrestin to T70C and K67C from ICL1 of rhodopsin. e, Structure and cross-linking of arrestin back loop residues R319C and T320C to Q237 ICL3 C from TM5 of rhodopsin. ARTICLE RESEARCH
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